Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

Satoru Nihei,Junya Sato,Toshiyuki Harada,Shoichi Kuyama,Toshiro Suzuki,Nobutsugu Waga,Yoshitaka Saito,Shigeki Kisara,Atsuko Yokota,Kouji Okada,Masami Tsuchiya,Terui K,Yumiko Tadokoro,Takeshi Chiba,Kenzo Kudo,Satoshi Oizumi,Akira Inoue,Naoto Morikawa

Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab

2018

Satoru Nihei
Junya Sato
Toshiyuki Harada
Shoichi Kuyama
Toshiro Suzuki
Nobutsugu Waga
Yoshitaka Saito
Shigeki Kisara
Atsuko Yokota
Kouji Okada
Masami Tsuchiya
Terui K
Yumiko Tadokoro
Takeshi Chiba
Kenzo Kudo
Satoshi Oizumi
Akira Inoue
Naoto Morikawa

Purpose The objective of this study was to investigate the effect of renin–angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients.

Keywords:

Bevacizumab
Proteinuria
Pharmacology
Cardiology
Renin–angiotensin system
Lung cancer
Internal medicine
Medicine
non small cell
Oncology
pharmacology toxicology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations